Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993616 · ClinicalTrials.gov registry record · Phase 2
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
A Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT00993616: Completed Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, sponsored by National Cancer Institute (NCI).
NCT00993616 is a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00993616, a Phase 2 study of Fallopian Tube Cancer and Primary Peritoneal Cavity Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well giving belinostat together with carboplatin works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that did not respond to carboplatin or cisplatin. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with carboplatin may kill more tumor cells.
Primary Outcome
Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (version 1.1): Complete Response (CR) is disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters; Increasing Disease is at least a 20% increase in the sum of the diameters of target lesion
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG belinostat
Study Locations (20)
Iowa
- Medical Oncology and Hematology Associates-West Des Moines - Clive
- Mercy Cancer Center-West Lakes - Clive
- Iowa Methodist Medical Center - Des Moines
- Iowa Oncology Research Association CCOP - Des Moines
- Medical Oncology and Hematology Associates-Des Moines - Des Moines
- Medical Oncology and Hematology Associates-Laurel - Des Moines
- Mercy Medical Center - Des Moines - Des Moines
- Iowa Lutheran Hospital - Des Moines
- University of Iowa Hospitals and Clinics - Iowa City
- Mercy Medical Center-West Lakes - West Des Moines
Kansas
- Menorah Medical Center - Overland Park
- Saint Luke's South Hospital - Overland Park
- Shawnee Mission Medical Center - Shawnee Mission
Connecticut
- Saint Francis Hospital and Medical Center - Hartford
- The Hospital of Central Connecticut - New Britain
Delaware
- Beebe Medical Center - Lewes
- Christiana Care Health System-Christiana Hospital - Newark
Illinois
- Rush University Medical Center - Chicago
Indiana
- Indiana University Medical Center - Indianapolis
Maryland
- Greater Baltimore Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-07-29 |
| Phase | Phase 2 |
What the finished NCT00993616 record still lists
NCT00993616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (89% lower).
The record links to 10 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.
NCT00993616 names 20 study sites across 7 states, led by Iowa, Kansas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00993616 about?
NCT00993616 is a clinical study titled "Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin". This phase II trial is studying how well giving belinostat together with carboplatin works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that did not respond to carboplatin or cisplatin. Belinostat may stop the growth...
What is the current status of trial NCT00993616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2009-12. Estimated completion is 2012-07-29.
What conditions does trial NCT00993616 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Epithelial Cancer, Ovarian Mucinous Cystadenocarcinoma.
What interventions are being tested in trial NCT00993616?
The interventions under investigation include: carboplatin (DRUG), belinostat (DRUG).
Who is sponsoring clinical trial NCT00993616?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00993616 being conducted?
This trial has 20 study locations across Connecticut, Delaware, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00993616's enrollment target sits among peer trials
29 68th of 85 higher than 17 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia